Metabolic Syndrome Prevalence in Renal Cell Cancer Patients

Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer

“…Finally, in a multivariate model including all 4 variables, hypertension maintained its significant association with the outcome variables when accounting for the variation introduced by the other metabolic syndrome components. (Table 4) These results further corroborate observations that hypertension has an association with RCC risk but also implicates a potential relationship with the biology underlying kidney cancer [15]. A variety of mechanisms has been proposed to explain the role of hypertension in carcinogenesis.…”

“…Overall, there was no significant difference in kidney cancer pathology between patients with and without metabolic syndrome. While patients with metabolic syndrome have been shown to have a higher prevalence of renal cell carcinoma [15], our study suggests that MetS is not associated with more adverse tumor features. Furthermore, only hypertension demonstrated an association with RCC pathology, including greater tumor size (P = 0.04), higher tumor grade (P = 0.04), increased nephrometry score (P = 0.001), and a trend toward higher tumor stage (P = 0.056).…”

The Effect of Framingham Score on the Oncological Outcomes in Localized (T1-T2 Stage) Renal Cell Carcinoma Patients

“…In the literature, there are many studies investigating the effect of metabolic syndrome, including impaired glucose tolerance /diabetes, obesity, high triglyceride levels, low HDL levels and hypertension on oncologic outcomes in RCC (8,9,24). Although there are some contradictory results, metabolic syndrome is thought to be a poor prognostic factor for RCC.…”

“…Although there are some contradictory results, metabolic syndrome is thought to be a poor prognostic factor for RCC. It is known that the incidence of RCC increases approximately 4-6 times in patients with three or more metabolic syndrome components (8). It was observed that the tumor size and grade were significantly higher in the presence of metabolic syndrome and that there was a correlation between individual hypertension, diabetes and high triglyceride levels with tumor aggressiveness (9).…”

“…The effects of presence and components of metabolic syndrome on oncologic outcomes in localized RCC have been investigated in many studies. The common belief in these studies is that the metabolic syndrome is a poor prognostic factor for RCC, that it increases the incidence of RCC approximately 4-6 times, leads to an increase in tumor size and stage, and significantly reduces progression-free survival (PFS) (8,9,10). Hypertension was found to be the worst prognostic risk factor in the publications investigating the effects of…”